Related Experiment Video

Updated: Aug 12, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

[Value of molecular markers for administration of anticoagulant therapy after heart valve replacement]

M Dahm1, J Lotz, G Hafner

  • 1Herzchirurgie, Universitätsklinik Mainz.

Zeitschrift Fur Kardiologie
|December 19, 1998
PubMed

Insights

Molecular markers like prothrombin fragment F1+2 and Factor II are superior to INR for monitoring early oral anticoagulation therapy (OAT) after valve replacement. High marker levels indicate continued thromboembolic risk despite therapeutic INR.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Oral anticoagulation therapy (OAT) is crucial for patients with mechanical heart valves.
  • Monitoring OAT effectiveness, particularly in the early phase, is vital to prevent thromboembolic events.
  • International Normalized Ratio (INR) is the standard measure for OAT monitoring.

Purpose of the Study:

  • To compare the efficacy of molecular markers versus INR in monitoring early OAT.
  • To assess the risk of thromboembolic events during the initial phase of OAT.

Main Methods:

  • Prospective study involving 39 patients undergoing aortic or mitral valve replacement.
  • Investigation of molecular markers (prothrombin fragment F1+2, Factor II) during early OAT.
  • Comparison of molecular marker levels with INR values.

Main Results:

  • Despite achieving the target INR range, molecular marker levels remained elevated in patients.
  • Elevated molecular markers indicated a persistent high risk of thromboembolic events.
  • Molecular markers provided a more sensitive assessment of anticoagulation status than INR.

Conclusions:

  • Molecular markers are superior to INR for monitoring the early phase of oral anticoagulation therapy.
  • Early identification of thromboembolic risk is improved by using molecular markers.
  • This suggests a potential shift in OAT monitoring protocols towards incorporating molecular markers.

More Related Videos

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...